Consistency and completeness of reported outcomes in randomized trials of primary immunosuppression in kidney transplantation

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 2892-2901

  Masson, P ^a,b   Duthie, F A ^c   Ruster, L P ^a   Kelly, P J ^a   Merrifield, A ^a   Craig, J C ^a,b   Webster, A C ^a,b,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Immunosuppression; kidney transplantation; outcome reporting; randomized trial; reporting bias; systematic review

Indexed keywords

ANTIMETABOLITE; CALCINEURIN INHIBITOR; CREATININE;

ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; OUTCOME REPORTING; RANDOMIZED TRIAL; REPORTING BIAS; SYSTEMATIC REVIEW;

HUMANS; IMMUNOSUPPRESSION; INFORMATION DISSEMINATION; KIDNEY TRANSPLANTATION; META-ANALYSIS AS TOPIC; PERIODICALS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; TREATMENT OUTCOME;

EID: 84886795760     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12444     Document Type: Article

References (23)

1. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. Br Med J 2010; 340: c365.
2. Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P., Comparison of registered and published primary outcomes in randomized controlled trials. J Am Med Assoc 2009; 302: 977-984.
3. Turner EH., A taxpayer-funded clinical trials registry and results database. PLoS Med 2004; 1: e60.
4. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC., Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4: CD003961.
5. Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
6. White CA, Siegal D, Akbari A, Knoll GA., Use of kidney function end points in kidney transplant trials: A systematic review. Am J Kidney Dis 2010; 56: 1140-1157.
7. Fritsche L, Einecke G, Fleiner F, Dragun D, Neumayer HH, Budde K., Reports of large immunosuppression trials in kidney transplantation: Room for improvement. Am J Transplant 2004; 4: 738-743.
8. Fleiner F, Fritsche L, Glander P, Neumayer H-H, Budde K., Reporting of rejection after renal transplantation in large immunosuppressive trials: Biopsy-proven, clinical, presumed, or treated rejection ? Transplantation 2006; 81: 655-659.
9. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006; 185: 263-267.
10. Ibrahim A, Garg AX, Knoll GA, Akbari A, White CA., Kidney function endpoints in kidney transplant trials: A struggle for power. Am J Transplant 2013; 13: 707-713.
11. Chan A-W, Hrõbjartsson A, Haahr MT, Gøtzsche PC, Altman DG., Empirical evidence for selective reporting of outcomes in randomized trials. J Am Med Assoc 2004; 291: 2457-2465.
12. Chan A-W, Altman DG., Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors. Br Med J 2005; 330: 753.
13. Chan A-W, Krleža-Jeric̈ K, Schmid I, Altman DG., Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. Can Med Assoc J 2004; 171: 735-740.
14. Al-Marzouki S, Roberts I, Evans S, Marshall T., Selective reporting in clinical trials: Analysis of trial protocols accepted by the Lancet. Lancet 2008; 372: 201.
15. Brooks RJ, Higgins GY, Webster AC., Systematic review of randomized controlled trial quality in pediatric kidney transplantation. Pediatr Nephrol 2010; 25: 2383-2392.
16. Hopewell S, Altman DG, Moher D, Schulz KF., Endorsement of the CONSORT Statement by high impact factor medical journals: A survey of journal editors and journal 'Instructions to Authors'. Trials 2008; 9: 20.
17. Smyth R, Kirkham J, Jacoby A, Altman D, Gamble C, Williamson P., Frequency and reasons for outcome reporting bias in clinical trials: Interviews with trialists. Br Med J 2011; 342: c7153.
18. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E., The COMET (core outcome measures in effectiveness trials) initiative. Trials 2011; 12: A70.
19. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L., OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007; 8: 38.
20. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012; 11: MR000030.
21. Bath PM, Iddenden R, Bath FJ., Low-molecular-weight heparins and heparinoids in acute ischemic stroke: A meta-analysis of randomized controlled trials. Stroke 2000; 31: 1770-1778.
22. Farrokhyar F, Chu R, Whitlock R, Thabane L., A systematic review of the quality of publications reporting coronary artery bypass grafting trials. Can J Surg 2007; 50: 266-277.
23. McGee RG, Su M, Kelly PJ, Higgins GY, Craig JC, Webster AC., Trial registration and declaration of registration by authors of randomized controlled trials. Transplantation 2011; 92: 1094-1100.